Duke researchers describe how breast cancer cells acquire drug resistance
A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues to overcome drug resistance, according to researchers at Duke Cancer Institute.
May 7, 2013
Immortality gene mutation identifies brain tumors and other cancers
Newly identified mutations in a gene that makes cells immortal appear to play a pivotal role in three of the most common types of brain tumors, as well as cancers of the liver, tongue and urinary tract, according to research led by Duke Cancer Institute.
Mar. 18, 2013
Sickle Cells Show Potential to Attack Aggressive Cancer Tumors
By harnessing the very qualities that make sickle cell disease a lethal blood disorder, a research team led by Duke Medicine and Jenomic, a private cancer research company in Carmel, Calif., has developed a way to deploy the misshapen red blood cells to fight cancer tumors.
Jan. 9, 2013
Five Duke Researchers Receive NIH Awards
Three researchers at Duke University Medical Center received prestigious young innovators awards from The National Institutes of Health, and two others won competitive grants to study kidney and urologic disease.
Sept. 13, 2012
New Breast Cancer Drug Halts Tumor Growth Better Than Standard Therapy
A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.
June 4, 2012